Data as of Mar 06
| 0.00 / 0.00%|
The 3 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 34.00, with a high estimate of 37.00 and a low estimate of 28.00. The median estimate represents a +24.50% increase from the last price of 27.31.
The current consensus among 4 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.